Once Weekly Parathyroid Hormone for Osteoporosis

NCT ID: NCT00065637

Last Updated: 2013-02-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-12-31
• Study Completion Date: 2005-09-30

Brief Summary

Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis. This study will evaluate the safety and effectiveness of PTH when given once a week.

Detailed Description

In osteoporosis, skeletal bone mass and strength are so reduced that fractures occur after only modest levels of mechanical stress that would not harm normal bone. Fractures of the hip, spine, and wrists are most typical, though fractures of the ribs, pelvis, and humerus also occur. Research has shown that hip fractures cause a 10% to 20% increase in mortality, and the cost of all osteoporotic fractures is estimated to be $6.14 billion in health care costs and lost earnings per year. The most common form of osteoporosis is postmenopausal osteoporosis. A reduction in bone mineral density of approximately 1% to 2% per year is observed for the first 3 to 5 years after the onset of menopause, then 0.5% to 1% per year thereafter.

PTH was recently approved by the FDA as a daily treatment for osteoporosis. However, PTH must be self-injected, is very expensive, and has been associated with worrisome side effects. The currently approved formulation of daily PTH self-injections is practical for only a small proportion of people with osteoporosis. A once weekly formulation could significantly decrease cost, difficulty of administration, and risks and side effects associated with daily use of PTH. A once weekly injection by a caregiver would also make PTH accessible to populations for whom daily self-injection may not be practical, such as the very elderly or those in assisted living or nursing homes. This study will evaluate the safety and effectiveness of once weekly PTH dosing for women with osteoporosis.

Women will be randomized to receive either PTH or placebo. Women will self-administer injections daily for 4 weeks, then once weekly for 48 weeks. All women will receive calcium and vitamin D supplements daily. Women will visit the clinic six times over the course of a year and will provide urine and blood samples at each visit. Bone mineral density will be measured at 6 and 12 months.

Conditions

Osteopenia; Osteoporosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

1

Women will self-administer PTH injections daily for 4 weeks, then once weekly for 48 weeks

Group Type: EXPERIMENTAL

Teriparatide

Intervention Type: DRUG

Synthetic human parathyroid hormone

2

Women will self-administer placebo injections daily for 4 weeks, then once weekly for 48 weeks

Group Type: PLACEBO_COMPARATOR

Placebo teriparatide

Intervention Type: DRUG

Placebo injections

Interventions

Teriparatide

Synthetic human parathyroid hormone

Intervention Type: DRUG

Placebo teriparatide

Placebo injections

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Bone mineral density scan with a T-score between -1 and -2
• Willing to self-administer injections
• Postmenopausal

Exclusion Criteria

• Medications to treat osteoporosis, including: hormone replacement therapy for more than one month in the 6 months prior to study, or for more than 12 months in the 2 years prior to study; alendronate, risedronate, or etidronate for more than 1 year anytime prior to study; calcitonin in the 3 months prior to study; taken raloxifene or tamoxifen in the last 6 months or for more than 1 year in the 2 years prior to study; fluoride for more than 1 month in the 5 years prior to study
• Bone fracture since menopause
• Femoral neck T-score below -2 AND lumbar spine T-score below -2.5 OR femoral neck T-score below -2.5 AND T-scores of both total hip and lumbar spine below -2

• Minimum Eligible Age: 45 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

Sponsor Role: collaborator

University of California, San Francisco

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clifford Rosen, MD

Role: PRINCIPAL_INVESTIGATOR

Unity Health Toronto

Locations

St Joseph Hospital

Bangor, Maine, United States

Countries

United States

References

Brown SA, Rosen CJ. Osteoporosis. Med Clin North Am. 2003 Sep;87(5):1039-63. doi: 10.1016/s0025-7125(03)00065-8.

Reference Type: BACKGROUND

PMID: 14621330 (View on PubMed)

Rosen CJ. The cellular and clinical parameters of anabolic therapy for osteoporosis. Crit Rev Eukaryot Gene Expr. 2003;13(1):25-38. doi: 10.1615/critreveukaryotgeneexpr.v13.i1.30.

Reference Type: BACKGROUND

PMID: 12839095 (View on PubMed)

Other Identifiers

N01AR002245-000

Identifier Type: NIH

Identifier Source: secondary_id

View Link

NIAMS-092

Identifier Type: -

Identifier Source: secondary_id

N01 AR32268

Identifier Type: -

Identifier Source: org_study_id